Inhibition Lysosomal Degradation of Clusterin by Protein Kinase D3 Promotes Triple‐Negative Breast Cancer Tumor Growth
Abstract Triple negative breast cancer (TNBC), with its lack of targeted therapies, shows the worst mortality rate among all breast cancer subtypes. Clusterin (CLU) is implicated to play important oncogenic roles in cancer via promoting various downstream oncogenic pathways. Here, protein kinase D3...
Main Authors: | Yan Liu, Yehui Zhou, Xinxing Ma, Liming Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-02-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202003205 |
Similar Items
-
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
by: Wei Cao, et al.
Published: (2019-02-01) -
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
by: Fleisher B, et al.
Published: (2016-10-01) -
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021-05-01) -
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01) -
A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
by: Alexandre de Nonneville, et al.
Published: (2019-08-01)